JP5933633B2 - サーチュイン１（ｓｉｒｔ１）遺伝子活性化剤及びテロメラーゼ逆転写酵素（ｔｅｒｔ）遺伝子活性化剤 - Google Patents
サーチュイン１（ｓｉｒｔ１）遺伝子活性化剤及びテロメラーゼ逆転写酵素（ｔｅｒｔ）遺伝子活性化剤 Download PDFInfo
- Publication number
- JP5933633B2 JP5933633B2 JP2014125633A JP2014125633A JP5933633B2 JP 5933633 B2 JP5933633 B2 JP 5933633B2 JP 2014125633 A JP2014125633 A JP 2014125633A JP 2014125633 A JP2014125633 A JP 2014125633A JP 5933633 B2 JP5933633 B2 JP 5933633B2
- Authority
- JP
- Japan
- Prior art keywords
- sirt1
- sirtuin
- agent
- activator
- gene transcription
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010041191 Sirtuin 1 Proteins 0.000 title claims description 129
- 239000012190 activator Substances 0.000 title claims description 97
- 108090000623 proteins and genes Proteins 0.000 title claims description 39
- 108010017842 Telomerase Proteins 0.000 title claims description 28
- 102100032938 Telomerase reverse transcriptase Human genes 0.000 title claims description 22
- 102100031455 NAD-dependent protein deacetylase sirtuin-1 Human genes 0.000 title claims 28
- 229920005610 lignin Polymers 0.000 claims description 75
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims description 71
- 235000011613 Pinus brutia Nutrition 0.000 claims description 71
- 241000018646 Pinus brutia Species 0.000 claims description 71
- 229930182470 glycoside Natural products 0.000 claims description 71
- 150000002338 glycosides Chemical class 0.000 claims description 70
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 66
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 33
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 33
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 33
- 229960001285 quercetin Drugs 0.000 claims description 33
- 235000005875 quercetin Nutrition 0.000 claims description 33
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 28
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical group C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 28
- 235000021283 resveratrol Nutrition 0.000 claims description 28
- 229940016667 resveratrol Drugs 0.000 claims description 28
- 239000003795 chemical substances by application Substances 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 23
- 235000013305 food Nutrition 0.000 claims description 21
- 239000004480 active ingredient Substances 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 17
- BFPLMTPHDFFMTG-UHFFFAOYSA-N [1,3]oxazolo[5,4-b]pyridine Chemical compound C1=CN=C2OC=NC2=C1 BFPLMTPHDFFMTG-UHFFFAOYSA-N 0.000 claims description 14
- 239000002537 cosmetic Substances 0.000 claims description 14
- IASPBORHOMBZMY-UHFFFAOYSA-N srt1720 Chemical compound C=1N=C2C=CC=CC2=NC=1C(=O)NC1=CC=CC=C1C(N=C1SC=2)=CN1C=2CN1CCNCC1 IASPBORHOMBZMY-UHFFFAOYSA-N 0.000 claims description 14
- 238000013518 transcription Methods 0.000 claims description 14
- 230000035897 transcription Effects 0.000 claims description 14
- 230000004913 activation Effects 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 11
- 206010012601 diabetes mellitus Diseases 0.000 claims description 9
- 150000004676 glycans Chemical class 0.000 claims description 9
- 229920001282 polysaccharide Polymers 0.000 claims description 9
- 239000005017 polysaccharide Substances 0.000 claims description 9
- 230000002757 inflammatory effect Effects 0.000 claims description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 230000007935 neutral effect Effects 0.000 claims description 4
- 235000000346 sugar Nutrition 0.000 claims description 4
- 206010029164 Nephrotic syndrome Diseases 0.000 claims description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- 230000017128 negative regulation of NF-kappaB transcription factor activity Effects 0.000 claims description 3
- 208000009928 nephrosis Diseases 0.000 claims description 3
- 231100001027 nephrosis Toxicity 0.000 claims description 3
- 230000036961 partial effect Effects 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 230000008085 renal dysfunction Effects 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 6
- 229920002770 condensed tannin Polymers 0.000 claims 5
- 239000003242 anti bacterial agent Substances 0.000 claims 4
- 239000003096 antiparasitic agent Substances 0.000 claims 4
- 229940125687 antiparasitic agent Drugs 0.000 claims 4
- 239000003443 antiviral agent Substances 0.000 claims 4
- 239000008280 blood Substances 0.000 claims 4
- 210000004369 blood Anatomy 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims 3
- 229930003268 Vitamin C Natural products 0.000 claims 3
- 239000003623 enhancer Substances 0.000 claims 3
- 235000019154 vitamin C Nutrition 0.000 claims 3
- 239000011718 vitamin C Substances 0.000 claims 3
- 206010012289 Dementia Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 150000003722 vitamin derivatives Chemical class 0.000 claims 1
- 102000000344 Sirtuin 1 Human genes 0.000 description 63
- 101150047500 TERT gene Proteins 0.000 description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 230000003712 anti-aging effect Effects 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 230000003449 preventive effect Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 229940124597 therapeutic agent Drugs 0.000 description 8
- 230000009471 action Effects 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 208000017169 kidney disease Diseases 0.000 description 6
- 208000024172 Cardiovascular disease Diseases 0.000 description 5
- 208000012902 Nervous system disease Diseases 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 230000002526 effect on cardiovascular system Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 108091035539 telomere Proteins 0.000 description 4
- 102000055501 telomere Human genes 0.000 description 4
- 210000003411 telomere Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000025500 Hutchinson-Gilford progeria syndrome Diseases 0.000 description 3
- 108010057466 NF-kappa B Proteins 0.000 description 3
- 102000003945 NF-kappa B Human genes 0.000 description 3
- 208000007932 Progeria Diseases 0.000 description 3
- -1 TNFalfa Proteins 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 2
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 102000011990 Sirtuin Human genes 0.000 description 2
- 108050002485 Sirtuin Proteins 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 230000006196 deacetylation Effects 0.000 description 2
- 238000003381 deacetylation reaction Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000000324 neuroprotective effect Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- ABDKAPXRBAPSQN-UHFFFAOYSA-N veratrole Chemical compound COC1=CC=CC=C1OC ABDKAPXRBAPSQN-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- 102100031249 H/ACA ribonucleoprotein complex subunit DKC1 Human genes 0.000 description 1
- 101710167047 H/ACA ribonucleoprotein complex subunit DKC1 Proteins 0.000 description 1
- 101000654472 Homo sapiens NAD-dependent protein deacetylase sirtuin-1 Proteins 0.000 description 1
- 101001087045 Homo sapiens Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Proteins 0.000 description 1
- 101100313319 Homo sapiens TERT gene Proteins 0.000 description 1
- 101000626112 Homo sapiens Telomerase protein component 1 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 102100032543 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Human genes 0.000 description 1
- 241000218641 Pinaceae Species 0.000 description 1
- 235000000405 Pinus densiflora Nutrition 0.000 description 1
- 240000008670 Pinus densiflora Species 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000011850 desserts Nutrition 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 125000003563 glycoside group Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Enzymes And Modification Thereof (AREA)
- Cosmetics (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014125633A JP5933633B2 (ja) | 2014-06-18 | 2014-06-18 | サーチュイン１（ｓｉｒｔ１）遺伝子活性化剤及びテロメラーゼ逆転写酵素（ｔｅｒｔ）遺伝子活性化剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014125633A JP5933633B2 (ja) | 2014-06-18 | 2014-06-18 | サーチュイン１（ｓｉｒｔ１）遺伝子活性化剤及びテロメラーゼ逆転写酵素（ｔｅｒｔ）遺伝子活性化剤 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011259573A Division JP5608629B2 (ja) | 2011-11-28 | 2011-11-28 | サーチュイン１（ｓｉｒｔ１）遺伝子活性化剤及びテロメラーゼ逆転写酵素（ｔｅｒｔ）遺伝子活性化剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014185170A JP2014185170A (ja) | 2014-10-02 |
| JP2014185170A5 JP2014185170A5 (enrdf_load_stackoverflow) | 2015-01-29 |
| JP5933633B2 true JP5933633B2 (ja) | 2016-06-15 |
Family
ID=51833061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014125633A Active JP5933633B2 (ja) | 2014-06-18 | 2014-06-18 | サーチュイン１（ｓｉｒｔ１）遺伝子活性化剤及びテロメラーゼ逆転写酵素（ｔｅｒｔ）遺伝子活性化剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5933633B2 (enrdf_load_stackoverflow) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106822152B (zh) * | 2016-12-28 | 2019-12-13 | 哈尔滨珍宝制药有限公司 | 一种药物组合物及其应用 |
| CN110343045B (zh) * | 2019-08-13 | 2021-11-12 | 中国科学院成都生物研究所 | 芳基四氢萘型木脂素类化合物及制备和应用 |
| EP4260863A4 (en) * | 2020-12-08 | 2024-09-04 | MD Healthcare Inc. | COMPOSITION FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL DISEASES OR PSYCHIATRIC DISEASES CONTAINING VESICLES FROM SPHINGOMONAS BACTERIA |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2784605B2 (ja) * | 1990-04-28 | 1998-08-06 | 靖一 田沼 | リグニン配糖体およびその用途 |
| JP2010540444A (ja) * | 2007-09-20 | 2010-12-24 | レスベラトロル パートナーズ， エルエルシー | 遺伝子産物の濃縮または活性を調節するためのレスベラトロールを含む組成物 |
-
2014
- 2014-06-18 JP JP2014125633A patent/JP5933633B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2014185170A (ja) | 2014-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5608629B2 (ja) | サーチュイン１（ｓｉｒｔ１）遺伝子活性化剤及びテロメラーゼ逆転写酵素（ｔｅｒｔ）遺伝子活性化剤 | |
| KR101966294B1 (ko) | 감태 추출물과 괭생이모자반 추출물을 이용한 항염증용 조성물 | |
| KR102178926B1 (ko) | 발효 태반 조성물을 유효성분으로 하는 면역 증강 또는 항피로 조성물과 그의 용도 | |
| JP5933633B2 (ja) | サーチュイン１（ｓｉｒｔ１）遺伝子活性化剤及びテロメラーゼ逆転写酵素（ｔｅｒｔ）遺伝子活性化剤 | |
| JP5813576B2 (ja) | サーチュイン１（ｓｉｒｔ１）遺伝子活性化剤 | |
| JP5948139B2 (ja) | サーチュイン１（ｓｉｒｔ１）遺伝子活性化剤 | |
| KR101666524B1 (ko) | 초과(Amomi Tsao-ko)로부터 분리된 화합물 및 이의 항염 용도 | |
| KR101471287B1 (ko) | 스피룰리나 맥시마 유래의 펩타이드를 유효성분으로 포함하는 알러지 관련 질환의 예방 또는 치료용 조성물 | |
| KR101982657B1 (ko) | 테트라세라 로우레이리 추출물을 이용한 항염증용 조성물 | |
| KR101520533B1 (ko) | 스피룰리나 맥시마 유래의 펩타이드를 유효성분으로 포함하는 심혈관 질환의 예방 또는 치료용 조성물 | |
| JP2017052750A (ja) | 新規エラジタンニンおよび口腔用剤 | |
| JP2007137775A (ja) | 破骨細胞分化抑制因子（ｏｐｇ）産生促進用組成物 | |
| JP5076104B2 (ja) | アレルギー体質改善剤 | |
| KR101798586B1 (ko) | 백미 추출물을 포함하는 아토피 피부염 치료용 조성물 | |
| JP2004002284A (ja) | リウマチの症状改善用飲食品および医薬 | |
| KR101851639B1 (ko) | 모과 추출물 또는 이의 분획물을 유효성분으로 함유하는 항비만용 조성물 | |
| KR101790409B1 (ko) | 지구자 추출물을 유효성분으로 포함하는 항비만용 조성물 | |
| KR101646002B1 (ko) | 주박 에탄올 추출물의 에틸아세테이트 분획물을 유효성분으로 함유하는 대장암의 예방 또는 치료용 약학적 조성물 및 건강 기능 식품 | |
| JP7428991B2 (ja) | 糖の吸収抑制用剤 | |
| KR100842054B1 (ko) | 구운감초 추출물 또는 이로부터 분리한 화합물을 포함하는혈당 강하용 조성물 | |
| KR102153338B1 (ko) | 카나리움 서부라텀(Canarium subulatum) 추출물을 유효성분으로 포함하는, 염증성 질환 예방 또는 치료용 약학적 조성물 | |
| KR101499286B1 (ko) | 시난디온 ａ를 포함하는 항염증용 조성물 | |
| JP2010031033A (ja) | リウマチの症状改善用飲食品 | |
| KR102318957B1 (ko) | 진세노사이드 mc 또는 mc1을 포함하는 대사성 질환 예방 또는 치료용 조성물 | |
| JP2017095409A (ja) | 筋萎縮阻害剤及びこれを含む食品並びに医薬品 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141128 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20141128 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141209 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20151006 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151207 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20151207 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160405 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160502 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5933633 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |